§ Claim under review · Mixed
"An independent lab sent a citizen's petition letter to the FDA claiming to have found high levels of the carcinogen benzene in several popular benzoyl peroxide containing acne treatments." (Instagram Reel, @rubin_allergy, published 2024-03-08)
Verdict
Accurate
Confidence
HighSummary
This claim is accurate. In early March 2024, an independent testing laboratory called Valisure did file a citizen petition with the FDA reporting that it had detected high levels of benzene, a known carcinogen, in numerous popular acne products containing benzoyl peroxide. Valisure said the benzene was not a contaminant but formed when the benzoyl peroxide itself broke down, especially when heated. However, the story did not end there, and this post is a snapshot from before the resolution. The FDA ran its own tests on 95 benzoyl peroxide acne products and announced in March 2025 that more than 90 percent had undetectable or extremely low benzene, with only six showing elevated levels, leading to a limited retail-level recall. The FDA also said that even with daily use for decades, the cancer risk from benzene found in these products is very low, and it criticized the unvalidated testing methods used by third-party labs. What remains genuinely unsettled is which testing conditions best reflect real-world storage and use, since Valisure's most dramatic numbers came from heating products to temperatures well above normal.
The readings
key figures from the evidenceFDA-tested acne products with undetectable or low benzene
benzene formation vs FDA's 2 ppm limit, per Valisure
Why this verdict
Evidence
The event described in the claim occurred essentially as stated. In March 2024, Valisure, an independent quality advocate, filed a citizen petition claiming to have detected elevated levels of benzene in benzoyl peroxide acne treatment products. Valisure's petition included testing results on over-the-counter brands from various retailers as well as prescription acne products.
Valisure, based in New Haven, Connecticut, filed the Citizen Petition on Benzene in Benzoyl Peroxide Drug Products on March 5, 2024.
Its press release stated that testing revealed benzene, a known human carcinogen, can form at high levels in BPO acne treatment products, and that on-market BPO products can form over 800 times the conditionally restricted FDA concentration limit of 2 parts per million.
The mechanism claimed was degradation, not contamination. The petition alleged that benzene formed in these products as a result of the degradation of the original formulation, not as a contaminant or added ingredient.
Valisure CEO David Light stated, "This is a problem of degradation, not contamination."
The requested remedy was substantial. Valisure requested that the FDA recall the products tested, conduct its own investigation and testing of these products and update its guidance on safe benzene levels.
The petition asked FDA "to issue a regulation, revise industry guidance, request a recall and suspend sales of benzoyl peroxide from the US market."
Critical subsequent development (occurred after this post): FDA conducted its own testing and largely did not replicate Valisure's alarming findings. In March 2025, the FDA announced it had tested 95 acne products containing benzoyl peroxide. More than 90% of the products tested had undetectable or extremely low levels of benzene. Six products had elevated levels of benzene, and as a result of this and other testing, the manufacturers of 7 products voluntarily recalled their products.
The recall was at the retail level, meaning retailers were instructed to remove products from shelves and online marketplaces, and the FDA did not instruct consumers to take any specific action.
FDA also characterized the absolute risk as low. The FDA added, "Even with daily use of these products for decades, the risk of a person developing cancer because of exposure to benzene found in these products is very low."
Findings
✓ What's accurate 8
- An independent laboratory (Valisure, New Haven, CT) did file a citizen petition with the FDA. Confirmed by the petition itself, FDA's response, USP, AARS, and multiple independent outlets.
- The filing date was March 5-6, 2024, consistent with the March 8, 2024 post date.
- The petition did claim high levels of benzene were found in benzoyl peroxide acne products.
- Benzene is correctly described as a known human carcinogen.
- "Several popular" products is accurate and, if anything, understated. Named products spanned major brands.
- The claim's hedge "claiming to have found" is precise. The post reports the assertion, it does not endorse it.
- The underlying chemistry claim was subsequently published in two peer-reviewed journals.
- FDA's own testing did find a small number of products with elevated benzene, resulting in real recalls.
≈ What's misleading 3
- **Omitted qualifier (in the broader discourse, not in this claim):** The widely circulated "800 times the FDA limit" figure required heating products to elevated temperatures. Valisure's room-temperature detections were far lower, though still above 2 ppm in 19 of 66 products.
- **Framing as fact vs. framing as assertion:** A citizen petition is an unadjudicated request to a regulator, not a regulatory finding. This claim correctly frames it as a claim, but many derivative posts did not.
- **Temporal limitation:** This post is a snapshot from March 2024. FDA's contradicting testing did not arrive until March 2025. Anyone encountering this post today without that update would form an incomplete picture.
? What's uncertain 4
- The scientific dispute over which testing protocol reflects real-world consumer conditions is not fully resolved. Valisure argues life-cycle stability testing is the correct standard. FDA and USP raised concerns about unvalidated modified methods.
- The reason for the divergence between Valisure's results and FDA's results is not definitively established in the sources reviewed. Possible explanations include different lots, different methods, different storage conditions, or manufacturer reformulation between 2024 and 2025.
- Whether real-world benzene exposure from these products has caused any measurable health harm is not established. FDA characterized the cancer risk as very low, but no long-term epidemiological outcome study specific to this exposure was located.
- I did not independently retrieve the full text of the FDA's formal response letter to the petition, only its March 11, 2025 public statement and secondary legal analyses of the response.
Sources
7 of 9 linked to records**Valisure FDA Citizen Petition on Benzene in Benzoyl Peroxide Drug Products (March 5, 2024)**
**FDA Statement, "Limited Number of Voluntary Recalls Initiated After FDA Testing of Acne Products; Benzene Findings Show..." (March 11, 2025)**
**Kucera K, et al. "Benzoyl Peroxide Drug Products Form Benzene." Environmental Health Perspectives 2024;132(3):37702. DOI: 10.1289/EHP13984**
**Kucera K, et al. "Evaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug Products." J Invest Dermatol 2025;145(5):1147-1154**
**US Pharmacopeia (USP) Statement on Third Party Laboratory Benzene Findings (March 8, 2024)**
**American Acne & Rosacea Society response statement (March 2024)**
**American Academy of Dermatology consumer FAQ on benzene in BPO products**
**Medscape, "Benzoyl Peroxide in Acne Products: Debates, Uncertainty Over Safety" (2024)**
**Skadden Arps client alert, "FDA Contradicts Benzene Class Actions" (March 2025)**